Category Archives: Global News Feed


Terranueva: Results of the Shareholders Meeting

L’ASSOMPTION, Quebec, April 14, 2022 (GLOBE NEWSWIRE) -- Terranueva Corporation (CSE: TEQ) ("Terranueva" or the "Company") is pleased to announce the results of its annual and special meeting of shareholders held on April 14, 2022. The shareholders approved, by a majority of votes, a resolution to elect the following directors: Sylvain Aird, Marc-André Aubé, Marianne Fortier-Landry, Gérard Landry, Jean-Luc Landry, Peter Polatos and Sylvain Tremblay. Also, the shareholders, by a majority of votes, proceeded with the appointment of PricewaterhouseCoopers LLP as auditors of the Corporation, as well as approved the Corporation’s Fixed Stock Option Plan in order to increase at 4,596,996 the maximum of common shares to be issued upon exercise of options, which represents 10% of the number of common share in the capital stock of Terranueva as of the record date of March 14, 2022.

See the original post:
Terranueva: Results of the Shareholders Meeting

Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

IRVINE, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it will host its first R&D Day on Thursday, April 28, 2022, from 10 a.m. to 12 p.m. ET (7 a.m. to 9 a.m. PT). Members of Eledon’s senior management team will be joined by four leading experts for a deep dive on the company’s investigational drug, tegoprubart, and the promise of CD40 Ligand targeted immunotherapy for the treatment of amyotrophic lateral sclerosis, kidney transplantation, islet cell transplantation, and IgA nephropathy.

Visit link:
Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

Angion Announces Participation in Upcoming Investment Conference

UNIONDALE, N.Y., April 14, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced participation in an upcoming investment conference.

Read more from the original source:
Angion Announces Participation in Upcoming Investment Conference

CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that John A. Scarlett, M.D. is retiring from its board of directors, effective when his current term expires at the company’s next annual meeting of stockholders, which is currently scheduled to be held on June 15, 2022.

Read more:
CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors

Vor Bio Announces Retirement of Chief Medical Officer

CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to actively recruit patients into VBP101, the Company’s Phase 1/2a first-in-human study of VOR33 in patients with AML who are at high risk of relapse. An executive search to replace Dr. Slapak is underway.

Go here to see the original:
Vor Bio Announces Retirement of Chief Medical Officer

LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market

PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certain institutional and accredited investors for $5.8 million of common stock. The Company issued a total of 2,900,000 shares of common stock at a purchase price of $2.00 per share.

Read more from the original source:
LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market